title: [Radiotherapy indications in non-Hodgkin lymphoma].
abstract: Actually, radiation-therapy indications in non-Hodgkin's lymphoma tends to decrease in favour of exclusive chemotherapy, especially in aggressive localized diseases. In this situation, PET scan imaging would be a promising tool to identify candidates to complementary radiotherapy after initial chemotherapy. To decrease long-term morbidity, radiation doses and treated volumes should be as small as possible. New radiation technologies could contribute to reduce this risk as well. However, there are still indications for radiotherapy. Radiation therapy could be delivered with curative-intent in localized indolent non-Hodgkin's lymphoma and could be helpful in symptom relief in advanced or relapsed indolent lymphoma.
authors.affiliation: Service de Cancérologie-Radiothérapie, Hôpital Saint-Louis, AP-HP, 75010 Paris cedex 10, France. laurent.quero@sls.aphp.fr
authors.forename: L
authors.initials: L
authors.lastname: Quero
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: P
authors.initials: P
authors.lastname: Brice
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy*; D010641:Phenotype; D011241:Prednisone / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone